Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc. (ACXP): 3 pipeline candidates · 1 upcoming catalyst · ~20 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
19.7 months
D/E 0.36 · 0% dilution
Lead: Phase 3
3 candidates
1 upcoming, next in ~62d
N/A
A transparent, data-derived signal for Acurx Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.6M
Cash
$9.3M
Quarterly Burn
$1.4M
Runway
19.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| ACX-375C | Preclinical |
| ibezapolstat | Phase 2 |
| ibezapolstat (formerly ACX-362E) | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
19
Total value held
$640K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 62,198 | $231K |
| jane street group, llc | 54,642 | $203K |
| geode capital management, llc | 24,819 | $92K |
| vanguard fiduciary trust co | 16,205 | $60K |
| morgan stanley | 6,500 | $24K |
| wells fargo & company/mn | 2,300 | $9K |
| nbc securities, inc. | 1,500 | $6K |
| western wealth management, llc | 1,325 | $5K |
| tower research capital llc (trc) | 1,031 | $4K |
| mcguire capital advisors inc | 1,000 | $4K |
Showing top 10 of 19 institutional holders of Acurx Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Acurx Pharmaceuticals, Inc.'s pipeline?
Acurx Pharmaceuticals, Inc. (ACXP) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Acurx Pharmaceuticals, Inc.'s lead drug candidate?
Acurx Pharmaceuticals, Inc.'s most advanced tracked candidate is ACX-375C (Preclinical) for Gram-positive bacteria, including MRSA, VRE and PRSP.
What is Acurx Pharmaceuticals, Inc.'s next catalyst?
Acurx Pharmaceuticals, Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 2 Interventional, Open-Label, Single-Arm Trial of Oral Ibezapolstat (ACX-362E) for Treatment" — expected August 19, 2026.
What is Acurx Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Acurx Pharmaceuticals, Inc. has approximately 19.7 months of cash runway.
What is Acurx Pharmaceuticals, Inc.'s market capitalization?
Acurx Pharmaceuticals, Inc.'s market capitalization is approximately $6.6M.
Get the full picture on Acurx Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.